138 related articles for article (PubMed ID: 15476054)
1. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats.
Chami N; Chami F; Bennis S; Trouillas J; Remmal A
Braz J Infect Dis; 2004 Jun; 8(3):217-26. PubMed ID: 15476054
[TBL] [Abstract][Full Text] [Related]
2. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo.
Chami N; Bennis S; Chami F; Aboussekhra A; Remmal A
Oral Microbiol Immunol; 2005 Apr; 20(2):106-11. PubMed ID: 15720571
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model.
Chami F; Chami N; Bennis S; Trouillas J; Remmal A
J Antimicrob Chemother; 2004 Nov; 54(5):909-14. PubMed ID: 15456732
[TBL] [Abstract][Full Text] [Related]
4. Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.
Martinez A; Regadera J; Jimenez E; Santos I; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Apr; 45(4):1008-13. PubMed ID: 11257009
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effects of carvacrol, nystatin, and their combination on oral candidiasis isolates.
Balef SSH; Hosseini SS; Asgari N; Sohrabi A; Mortazavi N
BMC Res Notes; 2024 Apr; 17(1):104. PubMed ID: 38605312
[TBL] [Abstract][Full Text] [Related]
7. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
8. Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans.
Melkoumov A; Goupil M; Louhichi F; Raymond M; de Repentigny L; Leclair G
J Antimicrob Chemother; 2013 Sep; 68(9):2099-105. PubMed ID: 23620465
[TBL] [Abstract][Full Text] [Related]
9. Use of photodynamic therapy and chitosan for inactivacion of Candida albicans in a murine model.
Fabio CA; Yolanda MB; Carmen GM; Francisco C; Antonio Julián B; Leonor PL; Jesús S
J Oral Pathol Med; 2016 Sep; 45(8):627-33. PubMed ID: 26991463
[TBL] [Abstract][Full Text] [Related]
10. Essential oil of Melaleuca alternifolia for the treatment of oral candidiasis induced in an immunosuppressed mouse model.
de Campos Rasteiro VM; da Costa AC; Araújo CF; de Barros PP; Rossoni RD; Anbinder AL; Jorge AO; Junqueira JC
BMC Complement Altern Med; 2014 Dec; 14():489. PubMed ID: 25510285
[TBL] [Abstract][Full Text] [Related]
11. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush.
Takakura N; Sato Y; Ishibashi H; Oshima H; Uchida K; Yamaguchi H; Abe S
Microbiol Immunol; 2003; 47(5):321-6. PubMed ID: 12825893
[TBL] [Abstract][Full Text] [Related]
12. [Sensitivity of Candida strains to polyenic antibiotics in the treatment of oral candidiasis].
Boĭko GI; Sosnin GP; Adarchenko AA; Moroz GS
Antibiotiki; 1984 Nov; 29(11):869-72. PubMed ID: 6395795
[TBL] [Abstract][Full Text] [Related]
13.
Li C; Xu Z; Liu S; Huang R; Duan W; Wei X
Biofouling; 2021 Sep; 37(8):818-829. PubMed ID: 34579611
[TBL] [Abstract][Full Text] [Related]
14. Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2).
Matsubara VH; Silva EG; Paula CR; Ishikawa KH; Nakamae AE
Oral Dis; 2012 Apr; 18(3):260-4. PubMed ID: 22059932
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activities of origanum oil against Candida albicans.
Manohar V; Ingram C; Gray J; Talpur NA; Echard BW; Bagchi D; Preuss HG
Mol Cell Biochem; 2001 Dec; 228(1-2):111-7. PubMed ID: 11855736
[TBL] [Abstract][Full Text] [Related]
16. Innovation of natural essential oil-loaded Orabase for local treatment of oral candidiasis.
Labib GS; Aldawsari H
Drug Des Devel Ther; 2015; 9():3349-59. PubMed ID: 26170621
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Antifungal Activity of Monolaurin against Candida albicans Biofilms.
Seleem D; Freitas-Blanco VS; Noguti J; Zancope BR; Pardi V; Murata RM
Biol Pharm Bull; 2018; 41(8):1299-1302. PubMed ID: 30068882
[TBL] [Abstract][Full Text] [Related]
18. An ex-vivo oral mucosa infection model for the evaluation of the topical activity of antifungal agents.
Ohnemus U; Willers C; Bubenheim M; Horstkotte MA; Houdek P; Fischer F; Schmage P; Moll I; Brandner JM
Mycoses; 2008 Jan; 51(1):21-9. PubMed ID: 18076591
[TBL] [Abstract][Full Text] [Related]
19. [Experimental oral candidiasis in healthy and immunocompromised BALB/c mice].
Karaman M; Kiray M; Bayrakal V; Bağrıyanık HA; Yılmaz O; Bahar IH
Mikrobiyol Bul; 2011 Apr; 45(2):336-43. PubMed ID: 21644077
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Candida albicans from patients with chronic oral candidiasis.
Holbrook WP; Kippax R
Postgrad Med J; 1979 Sep; 55(647):692-4. PubMed ID: 392486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
